BackGenMark Diagnostics Overview

GenMark Diagnostics Receivables

Track GenMark Diagnostics's receivables ($21M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$20.79M
24.05% YoYΔ $4.03M vs prior year quarter

Peer trimmed avg / median

Loading

GenMark Diagnostics Receivables History

Loading

GenMark Diagnostics vs. peers: Receivables Comparison

Loading

GenMark Diagnostics Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

GenMark Diagnostics (GNMK) FAQ

As of the most recent data (December 2020), GNMK shows a receivables of $21M. That compares with $17M in the prior-year period — up 24.1% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, GNMK's receivables is now $21M (was $17M) — a 24.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether GenMark Diagnostics is outperforming or lagging.

Tracking GNMK's receivables over time shows whether GenMark Diagnostics is scaling, shrinking, or reshaping that part of the business. The current reading is $21M That compares with $17M in the prior-year period — up 24.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has GenMark Diagnostics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $21M) with ownership activity and broader fundamentals.

GenMark Diagnostics's receivables is $21M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.